A Facebook post shares the trial figure and notes the drug is still investigational and has not been approved.
Recap by typeshit. Post by Facebook on Facebook.
He says close to 40% of weight lost in the trial's body-scan group was lean mass, and argues muscle loss isn't the drug's fault.
Wayne Pratt walks through what happens in the brain when drugs like Ozempic dial down the constant background chatter about eating.
Bikman cites a trial where people who lost about 21% and switched to placebo regained 14% within a year, while those who stayed on kept losing.
In Genome Medicine, diet-triggered delivery beat constant secretion on fat and liver fat, and kept down gut microbes carrying GLP-1-degrading peptidase genes.
2:58
A simple breakdown of how tirzepatide acts on two hormone pathways while retatrutide acts on three, from a pharmacist's channel.
The Tico Times reports Costa Rica's public system is considering offering GLP-1 weight loss drugs to patients. Tap through for where the discussion stands.
Loading…